Literature DB >> 28288980

Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.

Rut Valgardsdottir1, Irene Cattaneo2, Christian Klein3, Martino Introna1, Marina Figliuzzi2, Josée Golay1.   

Abstract

Polymorphonuclear neutrophils (PMNs) have previously been reported to mediate phagocytosis of anti-CD20-opsonized B cells from patients with chronic lymphocytic leukemia (CLL). However, recent data have suggested that PMNs, like macrophages, can also mediate trogocytosis. We have performed experiments to more precisely investigate this point and to discriminate between trogocytosis and phagocytosis. In live-cell time-lapse microscopy experiments, we could not detect any significant phagocytosis by purified PMNs of anti-CD20-opsonized CLL B cells, but could detect only the repeated close contact between effectors and targets, which suggested trogocytosis. Similarly, in flow cytometry assays using CLL B-cell targets labeled with the membrane dye PKH67 and opsonized with rituximab or obinutuzumab, we observed that a mean of 50% and 75% of PMNs had taken a fraction of the dye from CLL B cells at 3 and 20 hours, respectively, with no significant decrease in absolute live or total CLL B-cell numbers, confirming that trogocytosis occurs, rather than phagocytosis. Trogocytosis was accompanied by loss of membrane CD20 from CLL B cells, which was evident with rituximab but not obinutuzumab. We conclude that PMNs mediate mostly trogocytosis rather than phagocytosis of anti-CD20-opsonized CLL B cells, and we discuss the implications of this finding in patients with CLL treated with rituximab or obinutuzumab in vivo.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28288980     DOI: 10.1182/blood-2016-08-735605

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Trogocytosis-Mediated Intracellular Signaling in CD4+ T Cells Drives TH2-Associated Effector Cytokine Production and Differentiation.

Authors:  Jim Reed; Scott A Wetzel
Journal:  J Immunol       Date:  2019-04-08       Impact factor: 5.422

2.  Resolvin D1 promotes the targeting and clearance of necroptotic cells.

Authors:  Brennan D Gerlach; Michael Marinello; Justin Heinz; Nicholas Rymut; Brian E Sansbury; Colin O Riley; Sudeshna Sadhu; Zeinab Hosseini; Yoko Kojima; Dale D Tang; Nicholas J Leeper; Matthew Spite; Margarida Barroso; Katey J Rayner; Gabrielle Fredman
Journal:  Cell Death Differ       Date:  2019-06-20       Impact factor: 15.828

Review 3.  Targeting CD20: teaching an old dog new tricks.

Authors:  Jeff P Sharman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

4.  Assaying How Phagocytic Success Depends on the Elasticity of a Large Target Structure.

Authors:  Megan Davis-Fields; Layla A Bakhtiari; Ziyang Lan; Kristin N Kovach; Liyun Wang; Elizabeth M Cosgriff-Hernandez; Vernita D Gordon
Journal:  Biophys J       Date:  2019-09-13       Impact factor: 4.033

5.  Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation.

Authors:  Josée Golay; Rut Valgardsdottir; Gerta Musaraj; Damiano Giupponi; Orietta Spinelli; Martino Introna
Journal:  Blood       Date:  2019-01-17       Impact factor: 22.113

6.  Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair.

Authors:  Cathelijn E M Aarts; Ida H Hiemstra; Eelke P Béguin; Arjan J Hoogendijk; Souhailla Bouchmal; Michel van Houdt; Anton T J Tool; Erik Mul; Machiel H Jansen; Hans Janssen; Floris P J van Alphen; Jan-Paul de Boer; Charlotte L Zuur; Alexander B Meijer; Timo K van den Berg; Taco W Kuijpers
Journal:  Blood Adv       Date:  2019-11-26

7.  Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies.

Authors:  Mar Naranjo-Gomez; Jennifer Lambour; Marc Piechaczyk; Mireia Pelegrin
Journal:  JCI Insight       Date:  2018-05-03

8.  Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.

Authors:  Kyohei Nakamura; Mika Casey; Harald Oey; Frank Vari; John Stagg; Maher K Gandhi; Mark J Smyth
Journal:  Leukemia       Date:  2020-04-08       Impact factor: 11.528

Review 9.  B-cell Therapy for Multiple Sclerosis: Entering an era.

Authors:  Ariele L Greenfield; Stephen L Hauser
Journal:  Ann Neurol       Date:  2018-01       Impact factor: 10.422

10.  Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Authors:  Jakub Krejcik; Kris A Frerichs; Inger S Nijhof; Berris van Kessel; Jeroen F van Velzen; Andries C Bloem; Marloes E C Broekmans; Sonja Zweegman; Johan van Meerloo; René J P Musters; Pino J Poddighe; Richard W J Groen; Christopher Chiu; Torben Plesner; Henk M Lokhorst; A Kate Sasser; Tuna Mutis; Niels W C J van de Donk
Journal:  Clin Cancer Res       Date:  2017-10-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.